Advertisement
Advertisement
U.S. markets open in 25 minutes
Advertisement
Advertisement
Advertisement
Advertisement

INVO Bioscience, Inc. (INVO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0400-0.0200 (-1.89%)
At close: 03:20PM EDT
1.0800 +0.04 (+3.85%)
After hours: 07:13PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close1.0600
Open1.0200
Bid1.0400 x 1000
Ask1.0900 x 4000
Day's Range1.0200 - 1.0767
52 Week Range0.6300 - 4.2800
Volume15,823
Avg. Volume46,156
Market Cap12.581M
Beta (5Y Monthly)0.19
PE Ratio (TTM)N/A
EPS (TTM)-0.6260
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for INVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • INVO BioScience, Inc.
    Market Update: CENT, EBAY, PFE, VMC, RKTStocks were mostly higher on Thursday morning amid more signs of moderating inflation. The Labor Department said that its producer price index for final demand fell 0.5% in July, down from a 1.0% increase in June. The reading was the first negative number since April 2020 and below the Reuters consensus forecast, which called for an increase of 0.2%. The Dow rose 0.5%, the S&P rose 0.4%, and the Nasdaq was flat. Crude oil rose 1.5% to $93.50 per barrel, while gold rose $8 to $1806 per ounce.
    Rating
    Fair Value
    Economic Moat
    19 hours agoArgus Research
View more
  • PR Newswire

    INVO Bioscience to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022

    INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it enables, will report financial results for its second quarter 2022, ended June 30, 2022, after the market close on Monday, August 15, 2022. The Company has scheduled a conference call that same day, Monday, August 15, 2022, at 4:30 pm ET, to review the results.

  • PR Newswire

    INVO Bioscience Announces "Get to Know INVOcell" - a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment

    INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that Dr. Sue Ellen Carpenter of Bloom Fertility, an INVO Center in Atlanta, will be hosting "Get to Know INVOcell" - a Facebook Live Event on July 7, 2022 at 7 PM ET.

  • PR Newswire

    INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China

    INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has entered an exclusive distribution agreement with Onesky Holdings Limited ("Onesky") for Mainland China (excludes Hong Kong, Macau and Taiwan).

Advertisement
Advertisement